KR20220161444A - 새로운 살모넬라-기반의 코로나바이러스 백신 - Google Patents

새로운 살모넬라-기반의 코로나바이러스 백신 Download PDF

Info

Publication number
KR20220161444A
KR20220161444A KR1020227037910A KR20227037910A KR20220161444A KR 20220161444 A KR20220161444 A KR 20220161444A KR 1020227037910 A KR1020227037910 A KR 1020227037910A KR 20227037910 A KR20227037910 A KR 20227037910A KR 20220161444 A KR20220161444 A KR 20220161444A
Authority
KR
South Korea
Prior art keywords
cov
sars
protein
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037910A
Other languages
English (en)
Korean (ko)
Inventor
헤인즈 루벤나우
마크 만수르
Original Assignee
엔이씨 온코이뮤니티 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔이씨 온코이뮤니티 에이에스 filed Critical 엔이씨 온코이뮤니티 에이에스
Publication of KR20220161444A publication Critical patent/KR20220161444A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227037910A 2020-03-31 2021-03-31 새로운 살모넬라-기반의 코로나바이러스 백신 Pending KR20220161444A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20167405 2020-03-31
EP20167405.8 2020-03-31
PCT/EP2021/058513 WO2021198376A1 (en) 2020-03-31 2021-03-31 Novel salmonella-based coronavirus vaccine

Publications (1)

Publication Number Publication Date
KR20220161444A true KR20220161444A (ko) 2022-12-06

Family

ID=70110247

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037910A Pending KR20220161444A (ko) 2020-03-31 2021-03-31 새로운 살모넬라-기반의 코로나바이러스 백신

Country Status (8)

Country Link
US (1) US20230137174A1 (enExample)
EP (1) EP4126022A1 (enExample)
JP (1) JP2023519562A (enExample)
KR (1) KR20220161444A (enExample)
CN (1) CN115715198A (enExample)
AU (1) AU2021250442A1 (enExample)
CA (1) CA3170674A1 (enExample)
WO (1) WO2021198376A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
CN114517205A (zh) * 2020-11-20 2022-05-20 北京震旦鼎泰生物科技有限公司 融合基因及一种重组新型冠状病毒高效免疫鼎分子dna疫苗及其构建方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240515A1 (en) * 2003-07-21 2006-10-26 Dimitrov Dimiter S Soluble fragments of the SARS-CoV spike glycoprotein
WO2005030122A2 (en) * 2003-08-13 2005-04-07 Chiron Corporation Inactivated host cell delivery of polynucleotides encoding immunogens
CN1327900C (zh) * 2005-03-30 2007-07-25 武汉大学 一种染色体上携带病毒基因的减毒伤寒杆菌疫苗及制备方法
CA2853656C (en) 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
CA3063419A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
WO2020237246A1 (en) * 2019-05-23 2020-11-26 University Of Maryland, Baltimore Live attenuated non-transmissible vaccines
US10973908B1 (en) * 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Also Published As

Publication number Publication date
CA3170674A1 (en) 2021-10-07
AU2021250442A1 (en) 2022-11-10
US20230137174A1 (en) 2023-05-04
WO2021198376A1 (en) 2021-10-07
JP2023519562A (ja) 2023-05-11
CN115715198A (zh) 2023-02-24
EP4126022A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
US20250025544A1 (en) Immune checkpoint inhibitor co-expression vectors
JP7457733B2 (ja) 改変アデノウイルス
Flatz et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
KR102090612B1 (ko) 췌장암 환자용 dna 백신
KR20230025670A (ko) Sars-cov-2 백신
AU2019374874A1 (en) Alphavirus neoantigen vectors and interferon inhibitors
US20230128001A1 (en) Hiv antigens and mhc complexes
CA2890061A1 (en) Conditional replicating viral vectors
CN110430893A (zh) 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗
JP2024535855A (ja) Ｋｒａｓネオ抗原療法
KR20220161444A (ko) 새로운 살모넬라-기반의 코로나바이러스 백신
AU2018222777B9 (en) Novel VEGFR-2 targeting immunotherapy approach
US20230158133A1 (en) Wt1 targeting dna vaccine for combination therapy
AU2019334131B2 (en) Neoantigen targeting DNA vaccine for combination therapy
US20180153976A1 (en) Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
IL295546A (en) Neoantigens expressed in ovarian cancer and their uses
KR20220128638A (ko) 항생제와 조합되는 살모넬라-기반의 dna 백신
CA3009928C (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
CN103965288B (zh) 登革病毒特异性hla-a*2402限制性表位肽及应用
Steele Processing and presentation of a Chlamydia trachomatis antigen to CD8+ T cells
EA039715B1 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902